ENTRECTINIB

SynDRA canonical compound SYN0028865 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	ALK \| AURKB \| IGF1R \| NTRK1 \| NTRK2 \| NTRK3 \| ROS1
Mechanism of action	ALK tyrosine kinase receptor inhibitor \| proto-oncogene tyrosine protein kinase inhibitor
Indication	non-small cell lung cancer (NSCLC)
Disease area	oncology

All known targets

RXDX-101
NMS-E628
RG 6268
rozlytrek
Rozlytrek
UNII-L5ORF0AN1I
Entrectinib (RXDX-101)
L5ORF0AN1I
Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-
Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-
Entrectinib [USAN:INN]
YMX
Kinome_2659
Entrectinib(rxdx-101)
Entrectinib (USAN/INN)
SCHEMBL3512601
GTPL8290
CHEMBL1983268
KS-00000TSK
RXDX 101
entrectinibum
RXDX101
RefChem:58006
L01XE56
DTXCID101510637
MFCD28129099
Entrectinib [INN]
C31H34F2N6O2
Rozlytrek (TN)
Entrectinib, 95%
RG-6268
Entrectinib (Standard)
ENTRECTINIB [MI]
ENTRECTINIB [JAN]
Entrectinib; NMS-E628
ENTRECTINIB [USAN]
ENTRECTINIB [WHO-DD]
Entrectinib (RXDX-101)?